The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
New Avenues of Exploration for Erythropoietin
Open accessAbstract
Discovery that the hormone erythropoietin (EPO) and its receptor play a significant biological role in tissues outside of the hematopoietic system has fueled significant interest in EPO as a novel cytoprotective agent in both neuronal and vascular systems. Erythropoietin is now considered to have applicability in a variety of disorders that include cerebral ischemia, myocardial infarction, and chronic congestive heart failure. Erythropoietin modulates a broad array of cellular processes that include progenitor stem cell development, cellular integrity, and angiogenesis. As a result, cellular protection by EPO is robust and EPO inhibits the apoptotic mechanisms of injury, including the preservation of cellular membrane asymmetry to prevent inflammation. As the investigation into clinical applications for EPO that maximize efficacy and minimize toxicity progresses, a deeper appreciation for the novel roles that EPO plays in the brain and heart and throughout the entire body should be acquired.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization
Heeschen, C., Aicher, A., Lehmann, R., Fichtlscherer, S., Vasa, M., Urbich, C., Mildner-Rihm, C., Martin, H., Zeiher, A. M., & Dimmeler, S. (2003) · Blood · doi:10.1182/blood-2003-01-0223 · Cited by 845
Shingo, T., Sorokan, S. T., Shimazaki, T., & Weiss, S. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09733.2001 · Cited by 653
Silverberg, D. S., Wexler, D., Sheps, D., Blum, M., Keren, G., Baruch, R., Schwartz, D., Yachnin, T., Steinbruch, S., Shapira, I., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01248-7 · Cited by 644
Erythropoietin receptor mRNA expression in human endothelial cells.
Anagnostou, A., Liu, Z., Steiner, M., Chin, K., Lee, E. S., Kessimian, N., & Noguchi, C. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3974 · Cited by 570
A novel protective effect of erythropoietin in the infarcted heart
Parsa, C. J., Matsumoto, A., Kim, J., Riel, R. U., Pascal, L. S., Walton, G. B., Thompson, R. B., Petrofski, J. A., Annex, B. H., Stamler, J. S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18200 · Cited by 548
Mancini, D. M., Katz, S. D., Lang, C. C., LaManca, J., Hudaihed, A., & Androne, A.-S. (2003) · Circulation · doi:10.1161/01.cir.0000044914.42696.6a · Cited by 542
Ribatti, D., Presta, M., Vacca, A., Ria, R., Giuliani, R., Dell’Era, P., Nico, B., Roncali, L., & Dammacco, F. (1999) · Blood · doi:10.1182/blood.v93.8.2627 · Cited by 538
Grimm, C., Wenzel, A., Groszer, M., Mayser, H., Seeliger, M., Samardzija, M., Bauer, C., Gassmann, M., & Remé, C. E. (2002) · Nature Medicine · doi:10.1038/nm723 · Cited by 518
Ruscher, K., Freyer, D., Karsch, M., Isaev, N., Megow, D., Sawitzki, B., Priller, J., Dirnagl, U., & Meisel, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-23-10291.2002 · Cited by 462
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Efficacy and Safety of Epoetin Alfa in Critically Ill Patients
Corwin, H. L., Gettinger, A., Fabian, T. C., May, A., Pearl, R. G., Heard, S., An, R., Bowers, P. J., Burton, P., Klausner, M. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071533 · Cited by 545
Chong, Z. Z., Li, F., & Maiese, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.004 · Cited by 536
Self-citationPathologically activated therapeutics for neuroprotection
Lipton, S. A. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2229 · Cited by 257
OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins
Maiese, K., Chong, Z. Z., & Shang, Y. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.03.002 · Cited by 182
“For example, the ability of the growth factor and cytokine erythropoietin (EPO) to foster eythroid progenitor cell development is dependent upon the inhibition of FoxO3a activity [19,20], but also might require regulation of specific gene expression through an EPO–FoxO3a Maiese et al.”
BackgroundSelf-citationShedding new light on neurodegenerative diseases through the mammalian target of rapamycin
Chong, Z. Z., Shang, Y. C., Wang, S., & Maiese, K. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.001 · Cited by 119
Self-citationOxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
Maiese, K., Chong, Z. Z., Wang, S., & Shang, Y. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131113830 · Cited by 109
Self-citationMammalian target of rapamycin signaling in diabetic cardiovascular disease
Chong, Z., & Maiese, K. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-45 · Cited by 95
“Other therapeutic regiments that block oxidative stress in the vascular system involve the cytokine erythropoietin [56,69] and growth factors such as insulin growth factor [70].”
BackgroundSelf-citationCardiovascular Disease and mTOR Signaling
Chong, Z. Z., Shang, Y. C., & Maiese, K. (2011) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.04.005 · Cited by 87
Self-citationWang, S., Zhong Chong, Z., Chen Shang, Y., & Maiese, K. (2012) · Current Neurovascular Research · doi:10.2174/156720212800410858 · Cited by 63
Self-citationManagement of anemia of inflammation in the elderly
Macciò, A., & Madeddu, C. (2012) · Anemia · doi:10.1155/2012/563251 · Cited by 60
“The potential progression of cancer has been another significant concern raised with EPO administration [89].”
BackgroundSilverberg, D. S. (2011) · Heart Failure Reviews · doi:10.1007/s10741-010-9194-2 · Cited by 48
“These may explain its direct protective effects in experimental animals exposed to various hypoxic and toxic states [32, 33].”
Martini, S., Austin, T., Aceti, A., Faldella, G., & Corvaglia, L. (2020) · Pediatric Research · doi:10.1038/s41390-019-0639-6 · Cited by 50
Shang, Y., Chong, Z., Hou, J., & Maiese, K. (2009) · Current Neurovascular Research · doi:10.2174/156720209789630302 · Cited by 38
Self-citationSub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial
Stoppe, C., Ney, J., Brenke, M., Goetzenich, A., Emontzpohl, C., Schälte, G., Grottke, O., Moeller, M., Rossaint, R., & Coburn, M. (2016) · Sports Medicine · doi:10.1007/s40279-016-0505-1 · Cited by 31
Ferrer-Sapena, A., Sánchez-Pérez, E. A., Peset, F., González, L.-M., & Aleixandre-Benavent, R. (2016) · Research Evaluation · doi:10.1093/reseval/rvv041 · Cited by 27
Metadata
- Authors
- Maiese, K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-01-05
- Volume
- 293
- Issue
- 1
- Pages
- 90
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2028628328
- Cited by
- 528
- References
- 49
- FWCI
- 32.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.